Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges


#368558

182pages

Kelly Scientific Publications

$ 3400

In Stock

players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 265 tables & figures within 182 pages. The Chinese biopharmaceutical market is presented as follows:

  • By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)
  • By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)

A wealth of financial information is provided including:

  • Company financials, sales & revenue figures
  • China GDP, economic growth, export (bulk drug, formulations) figures
  • Indian health expenditure as a function of GDP
  • Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
  • Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)
  • Projected figures of strategic emerging industry GDP percentage contribution


SWOT, Economic and Business Environment specifics include:

  • Key strengths, weaknesses and threats influencing leading player position within the market
  • Top Five Contract Pharmaceutical Export Markets of China
  • Major players within China